Skip to main content
Clinical Trials/NCT00946036
NCT00946036CompletedPhase 1

Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fed Conditions

Torrent Pharmaceuticals Limited1 site in 1 countryStarted: July 24, 2009Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Locations
1

Study Overview

Brief Summary

  • Objective:

  • To compare the rate and extent of absorption of Torrent Pharmaceuticals Limited, India, sertraline and Pfizer, Inc., USA (Zoloft) sertaline, administered as a 1X100 mg tablet, under fasted conditions.

  • Study Design:

  • Single-dose, open-label, randomized two-way crossover.

Study Design

Study Type
Interventional

Eligibility Criteria

Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Male or female, smoker or non smoker, 18 years of age and older.
  • •Capable of consent.
  • •BMI>= 19.0 and <30.0 kg/m2

Exclusion Criteria

  • •Clinically significant illness or surgery within 4 weeks prior to the administration of the study medication.
  • •Positive testing for hepatitis B, hepatitis C, or HIV at screening.
  • •ECG abnormalities or vital sign abnormalities(blood pressure).
  • •History of significant alcohol or drug abuse within one year prior to the screening visit.
  • •History or allergic reactions to heparin, sertraline or other related drugs.
  • •Use of an investigational drug or participation in an investigational study with in 30 days prior to administration of the study medication.
  • •Clinically significant history of gastrointestinal pathology, liver or kidney disease, neurological, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.
  • •History of seizures, suicide attempt, bipolar disorder or manic episodes.
  • •Depot injection or an implant of any drugs with in 6 months prior to administration of study medication.
  • •Breastfeeding subject.
  • •Positive urine pregnancy test at screening.
  • •Female subject of child bearing potential having unprotected sexual intercourse with any non-sterile mail partner within 14 days prior to study drug administration. Acceptable methods of contraception:
  • •Intra-uterine contraceptive device(placed at least 4 weeks prior to study drug administration)
  • •Condom or diaphragm + spermicide.

Investigators

Sponsor Class
Industry

Study Sites (1)

Loading locations...

Similar Trials